MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: An immunohistochemical study including correlations with p53, bcl-2 and histological characteristics

Histopathology

Volumn 28, Issue 5, 1996, Pages 437-444

  Jensen, V ^a,b   Hoyer M ^a   Sorensen F B ^a   Keller, J ^a   Jensen, O M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University Institute of Pathology Arhus   (Denmark)

Author keywords

bcl 2; p53; Proliferative activity; Soft tissue sarcomas

Indexed keywords

IDOXURIDINE; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA;

EID: 0029951871     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.333377.x     Document Type: Article

References (41)

1. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsubara Y, Doi T. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988; 62; 994-998.
2. Ueda T, Aozasa K, Tsujimoto M et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63; 1607-1611.
3. Myhre Jensen O, Høgh J, Østgård SE, Nordentoft AM, Sneppen O. Histopathological grading of soft tissue tumors. Prognostic significance in a prospective study of 278 consecutive cases. J. Pathol. 1991, 163; 19-24.
4. Gerdes J, Lemke H, Baish H, Wacker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 133; 1710-1715.
5. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983; 31; 13-20.
6. Cattoretti G, Becker MHG, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992; 168; 357-363.
7. Shi S, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 1991; 39; 741-748.
8. Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J. Pathol. 1991; 163; 337-342.
9. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73; 2013-2026.
10. Hockenbery D, Nunez G, Milliman, C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348; 334-336.
11. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80; 879-886.
12. Oshiro Y, Fukuda T, Tsuneyoshi M. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53. Am. J. Surg. Pathol. 1994; 18; 712-719.
13. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342; 705-708.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253; 49-53.
15. Bártok J, Bártková J, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6; 1699-1703.
16. Andreassen Å, Oyjord T, Hovig E et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 1993; 53; 468-471.
17. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335; 675-679.
18. Enzinger FM, Weiss SW. Soft tissue tumours, 3rd ed. Mosby, 1995.
19. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218; 474-475.
20. Gundersen HJG. Notes on the estimation of the numerical density of arbitrary profiles: the edge effect. J. Microsc. 1987; 147; 229-263.
21. Bennet MH, Wilson GD, Dische S et al. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br. J. Cancer 1992; 65; 870-878.
22. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and application as prognostic variables. J. Pathol. 1990; 160; 93-102.
23. Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical application of morphological and immunocytochemical assessments of cell proliferation. Am. J. Clin. Pathol. 1992; 97; S4-S13.
24. Going JJ. Techniques of mitosis counting. Human Pathol. 1993; 24; 113-114.
25. Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988; 62; 989-993.
26. Lynch DAF, Clark AMT, Jackson P, Axon ATR, Dixon MF, Quirke P. Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J. Clin. Pathol. 1994; 47; 122-125.
27. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM, p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum. Pathol. 1994; 25; 1346-1352.
28. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic ligure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB-1 antibody. Hum. Pathol. 1994, 25; 337-342.
29. Silvestrini R, Costa A, Venerone G et al. Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet. 1988; 21; 123-131.
30. Leonardi E, Girlando S, Serio G et al. PCNA and Ki067 expression in breast carcinoma: Correlation with clin cal and biological variables. J. Clin. Pathol. 1992; 45; 416-419.
31. Porter PL, Gown AM, Kramp SG, Coltrera MC. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am. J. Pathol. 1992; 140; 145-153.
32. Kawai A, Nogushi M, Beppu Y et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 1994; 73; 2499-2505.
33. Sawan A, Randall B, Angus B et al. Retinoblstoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J. Pathol. 1992; 186; 23-28.
34. Walker RA, Hearing SAJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J. Pathol. 1991; 165; 203-211.
35. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas. Am. J. Clin. Pathol. 1992; 98; 408-418.
36. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer 1991; 63; 317-319.
37. Shurbaji MS, Kalbrfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol. 1995; 26; 106-109.
38. Korkolopoulou P, Oates J, Crocker J, Edwards C. p53 expression in oat and non-oat small cell lung carcinomas correlations with proliferating cell nuclear antigen. J. Clin. Pathol. 1993; 46; 1093-1096.
39. Soini Y, Vahakangas K, Nurova K, Kamel D, Lane DP, Paakko P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J. Pathol. 1992; 168; 29-33.
40. Barbareschi M, Iuzzolino P, Pennella A et al. p53 protein expression in central nervous system neoplams. J. Clin. Pathol. 1992; 45; 583-586.
41. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995; 75; 87-93.